Brain glucose metabolism shows shared dysfunction across Alzheimer's, Parkinson's, and ALS

Researchers analyzing over a decade of brain imaging studies have found something unexpected hiding in plain sight: three seemingly different neurodegenerative diseases—Alzheimer's, Parkinson's, and ALS—share a common metabolic signature in the brain, even as each disease damages the nervous system in its own distinct way.

The discovery emerged from a systematic review of 130 published studies involving more than 9,000 people—roughly 5,300 with one of these three conditions and 3,500 healthy controls. Scientists used a technique called FDG-PET imaging, which tracks how efficiently different brain regions consume glucose, the brain's primary fuel. They searched medical databases through July 2025, extracting precise coordinates of where metabolism was abnormally high or low in each patient group, then used statistical methods to identify patterns that held across multiple studies.

What they found was a paradox. All three diseases showed reduced glucose consumption in the cortex—the brain's outer layer responsible for higher thinking, memory, and motor control. This hypometabolism, or energy starvation, in cortical regions has long been recognized as a hallmark of neurodegeneration and likely explains much of the cognitive and motor decline patients experience. But the analysis also revealed something less discussed: simultaneously, other brain regions were burning glucose at abnormally high rates. These hypermetabolic zones clustered in deeper structures—the limbic system, cerebellum, and other subcortical areas—regions that maintain connections to the damaged cortical networks.

The spatial patterns differed meaningfully between diseases. Alzheimer's showed its own constellation of affected areas, Parkinson's another, and ALS a third. Yet beneath these disease-specific signatures lay this shared phenomenon: a brain struggling with energy regulation in opposite directions at the same time. The researchers propose that hypermetabolism in these deeper structures may represent a compensatory response—the brain attempting to maintain function by ramping up activity in regions still capable of working, trying to compensate for the failing cortex above.

But compensation is not the only possible explanation. Neuroinflammation—the chronic immune activation that accompanies neurodegeneration—could also drive increased glucose consumption in these subcortical regions. The data cannot yet distinguish between these mechanisms. What the analysis does establish is that treating these diseases as purely cortical problems may miss half the metabolic story. The brain in neurodegeneration is not simply shutting down; it is misfiring in both directions simultaneously.

The implications for treatment are substantial. Current approaches tend to focus on slowing the loss of function in damaged cortical regions or addressing disease-specific pathology—the amyloid plaques of Alzheimer's, the dopamine loss in Parkinson's, the motor neuron death in ALS. The new findings suggest that future therapies might need to address the broader metabolic dysregulation affecting the entire brain. Restoring balance to glucose metabolism—not just in one direction but across the whole system—could become as important as targeting the specific proteins or cells that each disease destroys. The research points toward a future where neurodegeneration treatment tackles both the disease-specific drivers and the shared metabolic chaos underlying them all.